These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 5305552)

  • 21. [Certain aspects of new combinations of drugs for the treatment of drug-resistant tuberculosis].
    Jancík E; Novák M; Jancíková M; Tousek J; Krátký J; Feitová S; Zelenka M
    Bull Int Union Tuberc; 1968 Dec; 41():188-91. PubMed ID: 5710247
    [No Abstract]   [Full Text] [Related]  

  • 22. [Bacterial resistance tests against secondary antitubercular agents--reliability of the routine methods].
    Tsukamura M
    Iryo; 1966 Mar; 20(3):241-50. PubMed ID: 5964831
    [No Abstract]   [Full Text] [Related]  

  • 23. [Urgent problems of antibacterial treatment of pulmonary tuberculosis].
    Pilipchuk NS
    Vrach Delo; 1981 Jan; (1):47-9. PubMed ID: 7010782
    [No Abstract]   [Full Text] [Related]  

  • 24. Surveillance of Mycobacterium tuberculosis susceptibility to second-line drugs in Hong Kong, 1995-2002, after the implementation of DOTS-plus.
    Kam KM; Yip CW
    Int J Tuberc Lung Dis; 2004 Jun; 8(6):760-6. PubMed ID: 15182147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the combination therapy of capreomycin. Ethionamide. Cycloserine with that of kanamycin. Ethionamide. Cycloserin in the retreatment of pulmonary tuberculosis.
    Kitamoto O; Oka S; Kawamori Y; Gomi J; Sugiyama K
    Jpn J Tuberc Chest Dis; 1970 Jul; 16(1):1-13. PubMed ID: 4990959
    [No Abstract]   [Full Text] [Related]  

  • 26. [Comparative study of two regimens, KM-TH-CS and KM-TH-EB, in retreatment cases of pulmonary tuberculosis].
    Aoyagi T; Fukuhara Y; Hondo G; Matsumiya T; Murata A
    Kekkaku; 1970 Jan; 45(1):27-36. PubMed ID: 5416951
    [No Abstract]   [Full Text] [Related]  

  • 27. [Effect and treatment problems of secondary antitubercular agents].
    Dissmann E
    Wien Med Wochenschr; 1966 Nov; 116(47):996-8. PubMed ID: 6011782
    [No Abstract]   [Full Text] [Related]  

  • 28. [Efficiency of interrupted therapy of tuberculosis (experimental study)].
    Drabkina RO; Ginzburg TS
    Antibiotiki; 1972 Jun; 17(6):555-60. PubMed ID: 5045922
    [No Abstract]   [Full Text] [Related]  

  • 29. [Ethambutol in the treatment of chronic pulmonary tuberculosis in patients excreting organisms resistant to several antitubercular agents].
    Bek-Lissner E; Rózewska M
    Gruzlica; 1971 Jul; 39(7):643-7. PubMed ID: 5000656
    [No Abstract]   [Full Text] [Related]  

  • 30. Drug therapy of resistant cases of pulmonary tuberculosis in Indian patients.
    Mital OP; Agarwala MC; Singh SK
    Indian J Chest Dis; 1967 Oct; 9(4):196-206. PubMed ID: 4323543
    [No Abstract]   [Full Text] [Related]  

  • 31. [Therapeutic effects of secondary antitubercular agents at our hospital].
    Nakayama K; Hayashida M; Ishihara M; Ijichi F; Obata Y
    Iryo; 1966 Mar; 20(3):257-63. PubMed ID: 5964832
    [No Abstract]   [Full Text] [Related]  

  • 32. [Clinical problems of resistance to secondary antitubercular agents].
    Baba H; Takahashi R; Nakai T; Torii R; Yo I
    Iryo; 1966 Mar; 20(3):230-40. PubMed ID: 5964830
    [No Abstract]   [Full Text] [Related]  

  • 33. [Depot drugs in the treatment of resistant forms of pulmonary tuberculosis. The experience of the Conjunto Sanatorial Octávio de Freitas (Recife)].
    Rizzo A; Moura N; Magalhães M; Antunes G; Campelo C
    Rev Bras Med; 1966 Dec; 23(12):850-2. PubMed ID: 5999012
    [No Abstract]   [Full Text] [Related]  

  • 34. Ethambutol in the treatment of 26 patients with chronic active pulmonary tuberculosis.
    Jesiotr M
    Tubercle; 1969 Mar; 50():Suppl:54-5. PubMed ID: 4319133
    [No Abstract]   [Full Text] [Related]  

  • 35. [Endocavernous treatment of caverns with atypical Mycobacteria].
    Neef W
    Z Erkr Atmungsorgane Folia Bronchol; 1970 Jun; 131(5):385-9. PubMed ID: 5210837
    [No Abstract]   [Full Text] [Related]  

  • 36. [Observations on antituberculous drug-resistance among pulmonary tuberculosis patients at the National Sanatoria in Kyushu district. 3. The secondary anti-tuberculosis agents (kanamycin, cycloserine, ethionamide)].
    Yamaguchi S
    Iryo; 1968 Oct; 22(10):1115-9. PubMed ID: 5715475
    [No Abstract]   [Full Text] [Related]  

  • 37. [Four drug combination including Ethambutol and early switching to entirely new regimen in initial treatment of pulmonary tuberculosis].
    Kekkaku; 1970 Jul; 45(7):219-26. PubMed ID: 5449509
    [No Abstract]   [Full Text] [Related]  

  • 38. [Ethambutol, capreomycin and rifampicin in lung tuberculosis].
    Hellström PE; Repo UK
    Nord Med; 1968 Dec; 79(51):1723-9. PubMed ID: 5712754
    [No Abstract]   [Full Text] [Related]  

  • 39. In vitro and in vivo studies to assess the suitability of anti-tuberculous drugs for use in intermittent chemotherapy regimens.
    Dickinson JM
    Bull Int Union Tuberc; 1968 Dec; 41():309-15. PubMed ID: 4179554
    [No Abstract]   [Full Text] [Related]  

  • 40. [Results of treatment of chronic destructive pulmonary tuberculosis with reserve tuberculostatic preparations including some new preparations].
    Rabukhin AE; Alekseeva VM; Ivanova ES; Kubyshkina VF; Kliuchareva EA
    Probl Tuberk; 1970; 48(8):18-22. PubMed ID: 5496733
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.